Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease
Dopaminergic stimulation with levodopa, a biological precursor of dopamine precursor, and dopamine receptor agonists (DRA) remains the leading pharmacotherapeutic strategy for Parkinson’s disease (PD). The long-term use of levodopa is associated with the development of characteristic fluctuations in...
Main Author: | S N Illarioshkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2012-06-01
|
Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
Subjects: | |
Online Access: | https://nnp.ima-press.net/nnp/article/view/129 |
Similar Items
-
Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients
by: Angela Deutschländer, et al.
Published: (2016-01-01) -
Sustained-release pramipexole in the treatment of Parkinson’s disease
by: Natalia Vladimirovna Fedorova
Published: (2012-03-01) -
USE OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY-STAGE PARKINSON’S DISEASE: DESCRIPTION OF A CLINICAL CASE
by: N. V. Fedorova, et al.
Published: (2014-11-01) -
USE OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY-STAGE PARKINSON’S DISEASE: DESCRIPTION OF A CLINICAL CASE
by: N. V. Fedorova, et al.
Published: (2014-11-01) -
Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole
by: M. R. Nodel
Published: (2011-12-01)